Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06109870 · ClinicalTrials.gov registry record · NA

Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening

A NA study of Hpv, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
920
Enrollment target
2
Study locations

NCT06109870 is a NA study of Hpv that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 920 participants, below the 2,203-participant average among 24 other Hpv trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06109870, a NA study of Hpv, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
920 participants
Enrollment target
2
Study locations

Study Summary

Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.

Conditions Studied

Interventions

  • BEHAVIORAL PRECEDE-PROCEED

Study Locations (2)

Texas

  • University of Texas at Austin - Austin
  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 920 participants
Start Date 2023-10-30
Est. Completion 2030-08-31
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT06109870

The ClinicalTrials.gov registry entry for NCT06109870 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 920 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,203-participant average among 24 other Hpv trials with a reported enrollment target (58% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hpv appearing as the primary indexed condition, and to 1 intervention - of which PRECEDE-PROCEED is the first listed.

NCT06109870 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06109870 about?

NCT06109870 is a clinical study titled "Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening". Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.

What is the current status of trial NCT06109870?

This trial is currently recruiting. It is a NA study. The enrollment target is 920 participants. The study started on 2023-10-30. Estimated completion is 2030-08-31.

What conditions does trial NCT06109870 study?

This clinical trial studies the following conditions: Hpv.

What interventions are being tested in trial NCT06109870?

The interventions under investigation include: PRECEDE-PROCEED (BEHAVIORAL).

Who is sponsoring clinical trial NCT06109870?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06109870 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hpv

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.